USE OF CYTOCHROME P450-METABOLIZED DRUGS AND GRF MOLECULES IN COMBINATION THERAPY
Combination therapies comprising a drug metabolized by cytochrome P450 and a growth hormone (GH)-inducing compound (such as a GRF molecule) are described, in which there are no or substantially no drug interactions.
1 . A method of inducing GH levels in a subject undergoing a treatment regimen with or who is a candidate for a treatment regimen with a CYP-metabolized compound, without modifying said treatment regimen, said method comprising administering to said subject an effective amount of (hexenoyl trans-3)hGRF(1-44)NH 2 .
2 . A method of treating excess abdominal fat in a HIV-infected subject with lipodystrophy, wherein said subject is undergoing treatment with or is a candidate for treatment with a CYP-metabolized compound, without modifying said treatment regimen, said method comprising administering to said subject an effective amount of (hexenoyl trans-3)hGRF(1-44)NH 2 .
3 . The method of claim 1 , wherein said method further comprises selecting a subject who is undergoing, or who is a candidate for, a treatment regimen with a CYP-metabolized compound.
4 . The method of claim 2 , wherein said method further comprises selecting a subject who is undergoing, or who is a candidate for, a treatment regimen with a CYP-metabolized compound.
5 . A method comprising providing information to a subject or to a caregiver of the subject that (hexenoyl trans-3)hGRF(1-44)NH 2 and a CYP-metabolized compound can be co-administered to the subject.
6 . The method of claim 5 , further comprising providing information to the subject or to the caregiver of the subject that (hexenoyl trans-3)hGRF(1-44)NH 2 can be co-administered to the subject without significantly affecting pharmacokinetics of the CYP-metabolized compound.
7 . The method of claim 5 , further comprising providing information to the subject or to the caregiver of the subject that (hexenoyl trans-3)hGRF(1-44)NH 2 can be co-administered to the subject without modifying the treatment regimen of the CYP-metabolized compound.
8 . The method of any one of claims 5 , further comprising selecting a subject who is undergoing, or who is a candidate for, a treatment regimen with (hexenoyl trans-3)hGRF(1-44)NH 2 and with a CYP-metabolized compound.
9 . The method of claim 1 , wherein the CYP-metabolized compound is a statin.
10 . The method of claim 9 , wherein the statin is simvastatin.
11 . The method of claim 2 , wherein the GYP-metabolized compound is a statin.
12 . The method of claim 11 , wherein the statin is simvastatin.
13 . The method of claim 5 , wherein the CYP-metabolized compound is a statin.
14 . The method of claim 13 , wherein the statin is simvastatin.
15 . The method of claim 1 , wherein the (hexenoyl trans-3)hGRF(1-44)NH 2 is administered at a daily dose of about 2 mg.
16 . The method of claim 1 , wherein the (hexenoyl trans-3)hGRF(1-44)NH 2 is administered subcutaneously.
17 . The method of claim 2 , wherein the (hexenoyl trans-3)hGRF(1-44)NH 2 is administered at a daily dose of about 2 mg.
18 . The method of claim 2 , wherein the (hexenoyl trans-3)hGRF(1-44)NH 2 is administered subcutaneously.
19 . The method of claim 5 , wherein the (hexenoyl trans-3)hGRF(1-44)NH 2 is administered at a daily dose of about 2 mg.
20 . The method of claim 5 , wherein the (hexenoyl trans-3)hGRF(1-44)NH 2 is administered subcutaneously.